Polypharmacology by Design: A Medicinal Chemist's Perspective on Multitargeting Compounds.
暂无分享,去创建一个
[1] István A. Kovács,et al. How to design multi-target drugs , 2007, Expert opinion on drug discovery.
[2] Laura M. Geffert,et al. SKI-178: A multitargeted inhibitor of sphingosine kinase and microtubule dynamics demonstrating therapeutic efficacy in acute myeloid leukemia models , 2017, Cancer translational medicine.
[3] Jacob de Vlieg,et al. Comparative Analysis of Pharmacophore Screening Tools , 2012, J. Chem. Inf. Model..
[4] Anne W. Schmidt,et al. 1-Naphthylpiperazine derivatives as potential atypical antipsychotic agents. , 1991, Journal of medicinal chemistry.
[5] Robert J Kavlock,et al. Phenotypic screening of the ToxCast chemical library to classify toxic and therapeutic mechanisms , 2014, Nature Biotechnology.
[6] Michael J. Keiser,et al. Leveraging Large-scale Behavioral Profiling in Zebrafish to Explore Neuroactive Polypharmacology. , 2016, ACS chemical biology.
[7] Holger Stark,et al. Development of a new class of nonimidazole histamine H(3) receptor ligands with combined inhibitory histamine N-methyltransferase activity. , 2002, Journal of medicinal chemistry.
[8] Lazaros Mavridis,et al. Predicting targets of compounds against neurological diseases using cheminformatic methodology , 2015, Journal of Computer-Aided Molecular Design.
[9] Chuda Chittasupho. Multivalent ligand: design principle for targeted therapeutic delivery approach. , 2012, Therapeutic delivery.
[10] Wei Li,et al. Prediction of synergistic anti-cancer drug combinations based on drug target network and drug induced gene expression profiles , 2017, Artif. Intell. Medicine.
[11] Krister Wennerberg,et al. Methods for High-Throughput Drug Combination Screening and Synergy Scoring , 2016, bioRxiv.
[12] Yanli Wang,et al. PubChem BioAssay: 2017 update , 2016, Nucleic Acids Res..
[13] Jin-jian Lu,et al. Multi-Target Drugs: The Trend of Drug Research and Development , 2012, PloS one.
[14] Sheng-Yong Yang,et al. Pharmacophore modeling and applications in drug discovery: challenges and recent advances. , 2010, Drug discovery today.
[15] D. Sejer Pedersen,et al. Bitopic Ligands and Metastable Binding Sites: Opportunities for G Protein-Coupled Receptor (GPCR) Medicinal Chemistry. , 2017, Journal of medicinal chemistry.
[16] U. Kintscher,et al. Characterization of New PPARγ Agonists: Analysis of Telmisartan’s Structural Components , 2009, ChemMedChem.
[17] S. Shaw,et al. Soluble epoxide hydrolase inhibition and peroxisome proliferator activated receptor γ agonist improve vascular function and decrease renal injury in hypertensive obese rats , 2012, Experimental biology and medicine.
[18] T. Efferth,et al. Network pharmacology of cancer: From understanding of complex interactomes to the design of multi-target specific therapeutics from nature. , 2016, Pharmacological research.
[19] Alimuddin Zumla,et al. Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosis , 2016, BMC Medicine.
[20] H. Brückmann,et al. Polypharmacology of dopamine receptor ligands , 2016, Progress in Neurobiology.
[21] C. Cava,et al. In silico identification of drug target pathways in breast cancer subtypes using pathway cross-talk inhibition , 2018, Journal of Translational Medicine.
[22] J. Ohren,et al. Discovery of a series of imidazo[4,5-b]pyridines with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ. , 2011, Journal of medicinal chemistry.
[23] Robert J Gillies,et al. Hitting multiple targets with multimeric ligands , 2004, Expert opinion on therapeutic targets.
[24] George Karypis,et al. Target Fishing for Chemical Compounds Using Target-Ligand Activity Data and Ranking Based Methods , 2009, J. Chem. Inf. Model..
[25] Andreas Bender,et al. DeepSynergy: predicting anti-cancer drug synergy with Deep Learning , 2017, Bioinform..
[26] Oliver Koch,et al. A novel interaction fingerprint derived from per atom score contributions: exhaustive evaluation of interaction fingerprint performance in docking based virtual screening , 2018, Journal of Cheminformatics.
[27] E. Wong,et al. The effectiveness of multi-target agents in schizophrenia and mood disorders: Relevance of receptor signature to clinical action. , 2010, Pharmacology & therapeutics.
[28] Gisbert Schneider,et al. De Novo Design of Bioactive Small Molecules by Artificial Intelligence , 2018, Molecular informatics.
[29] M. Murcko,et al. Kinase-likeness and kinase-privileged fragments: toward virtual polypharmacology. , 2008, Journal of medicinal chemistry.
[30] Om Silakari,et al. Multifunctional compounds: smart molecules for multifactorial diseases. , 2014, European journal of medicinal chemistry.
[31] A. Simeonov,et al. Drug discovery and development for rare genetic disorders , 2017, American journal of medical genetics. Part A.
[32] B. Cravatt,et al. Synergy between Enzyme Inhibitors of Fatty Acid Amide Hydrolase and Cyclooxygenase in Visceral Nociception , 2009, Journal of Pharmacology and Experimental Therapeutics.
[33] Maria Laura Bolognesi,et al. Memoquin: A multi-target-directed ligand as an innovative therapeutic opportunity for Alzheimer’s disease , 2011, Neurotherapeutics.
[34] Judith M. Rollinger,et al. Accessing target information by virtual parallel screening—The impact on natural product research , 2009 .
[35] C. Saxena. Identification of protein binding partners of small molecules using label-free methods , 2016, Expert opinion on drug discovery.
[36] D. Steinhilber,et al. Inhibitors of the arachidonic acid cascade: interfering with multiple pathways. , 2014, Basic & clinical pharmacology & toxicology.
[37] Andreas Bender,et al. Prediction of Antibiotic Interactions Using Descriptors Derived from Molecular Structure. , 2017, Journal of medicinal chemistry.
[38] J. Peters. Polypharmacology - foe or friend? , 2013, Journal of medicinal chemistry.
[39] Huey Eng Chua,et al. Synergistic target combination prediction from curated signaling networks: Machine learning meets systems biology and pharmacology. , 2017, Methods.
[40] R. Ramsay,et al. Key Targets for Multi-Target Ligands Designed to Combat Neurodegeneration , 2016, Front. Neurosci..
[41] Olivier Elemento,et al. A Computational Approach for Identifying Synergistic Drug Combinations , 2017, PLoS Comput. Biol..
[42] A. Connor,et al. ADME and Safety Aspects of Non-cleavable Linkers in Drug Discovery and Development. , 2018, Current Topics in Medicinal Chemistry.
[43] G. Drewes,et al. Thermal proteome profiling for unbiased identification of direct and indirect drug targets using multiplexed quantitative mass spectrometry , 2015, Nature Protocols.
[44] D. Lauro,et al. Pleiotropic effects of hypoglycemic agents: implications in asthma and COPD , 2018, Current opinion in pharmacology.
[45] Thierry Langer,et al. Molecule-pharmacophore superpositioning and pattern matching in computational drug design. , 2008, Drug discovery today.
[46] B. Potter,et al. Hybrid dual aromatase-steroid sulfatase inhibitors with exquisite picomolar inhibitory activity. , 2011, ACS medicinal chemistry letters.
[47] Shenghua Shi,et al. Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent , 2009, Proceedings of the National Academy of Sciences.
[48] Norbert Handler,et al. Pharmacophore Generation for Multiple Ligands , 2017 .
[49] Gilles Marcou,et al. Hot-Spots-Guided Receptor-Based Pharmacophores (HS-Pharm): A Knowledge-Based Approach to Identify Ligand-Anchoring Atoms in Protein Cavities and Prioritize Structure-Based Pharmacophores , 2008, J. Chem. Inf. Model..
[50] S. Salomone,et al. New drugs in psychiatry: focus on new pharmacological targets , 2017, F1000Research.
[51] I. Amelio,et al. Polypharmacology of Approved Anticancer Drugs. , 2017, Current drug targets.
[52] Avner Schlessinger,et al. A Whole Animal Platform to Advance A Clinical Kinase Inhibitor Into New Disease Space , 2017, Nature chemical biology.
[53] Liao Jie-Lou Jeffrey and Andrews C. Robert,et al. Targeting protein multiple conformations: a structure-based strategy for kinase drug design. , 2007 .
[54] K. Shokat,et al. Targeted polypharmacology: Discovery of dual inhibitors of tyrosine and phosphoinositide kinases , 2008, Nature chemical biology.
[55] M. Frigerio,et al. The Chemical Design and Synthesis of Linkers Used in Antibody Drug Conjugates. , 2018, Current topics in medicinal chemistry.
[56] J. Bajorath,et al. Polypharmacology: challenges and opportunities in drug discovery. , 2014, Journal of medicinal chemistry.
[57] Rona R. Ramsay,et al. One for All? Hitting Multiple Alzheimer's Disease Targets with One Drug , 2016, Front. Neurosci..
[58] Maurizio Recanatini,et al. Multi-target-directed ligands to combat neurodegenerative diseases. , 2008, Journal of medicinal chemistry.
[59] A. Ganesan,et al. Epigenetic polypharmacology: from combination therapy to multitargeted drugs , 2016, Clinical Epigenetics.
[60] Paola Bisignano,et al. Development and Application of a Virtual Screening Protocol for the Identification of Multitarget Fragments , 2016, ChemMedChem.
[61] Andreas Evers,et al. MARS: Computing Three-Dimensional Alignments for Multiple Ligands Using Pairwise Similarities , 2012, J. Chem. Inf. Model..
[62] B. Potter,et al. Synthesis and Structure–Activity Relationship Studies of Derivatives of the Dual Aromatase–Sulfatase Inhibitor 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate , 2013, ChemMedChem.
[63] Daniel Moser,et al. Dual-target virtual screening by pharmacophore elucidation and molecular shape filtering. , 2012, ACS medicinal chemistry letters.
[64] Yuan Sun,et al. Designing multi-targeted agents: An emerging anticancer drug discovery paradigm. , 2017, European journal of medicinal chemistry.
[65] L. Wodicka,et al. Dual kinase-bromodomain inhibitors for rationally designed polypharmacology , 2014, Nature chemical biology.
[66] P. Low,et al. Principles in the design of ligand-targeted cancer therapeutics and imaging agents , 2015, Nature Reviews Drug Discovery.
[67] Z. An,et al. Antibody-drug conjugates: recent advances in conjugation and linker chemistries , 2016, Protein & Cell.
[68] Andreas Bender,et al. Computer-aided design of multi-target ligands at A1R, A2AR and PDE10A, key proteins in neurodegenerative diseases , 2017, Journal of Cheminformatics.
[69] O. Melnyk,et al. Assembly/disassembly of drug conjugates using imide ligation. , 2010, Organic letters.
[70] B. Roth,et al. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia , 2004, Nature Reviews Drug Discovery.
[71] Lu Huang,et al. Predicting Drug Combination Index and Simulating the Network-Regulation Dynamics by Mathematical Modeling of Drug-Targeted EGFR-ERK Signaling Pathway , 2017, Scientific Reports.
[72] N. M. Raghavendra,et al. Dual or multi-targeting inhibitors: The next generation anticancer agents. , 2018, European journal of medicinal chemistry.
[73] Erwan Bezard,et al. Modeling Parkinson's disease in primates: The MPTP model. , 2012, Cold Spring Harbor perspectives in medicine.
[74] L. Altucci,et al. Targeting epigenetic networks with polypharmacology: a new avenue to tackle cancer. , 2010, Epigenomics.
[75] C. Walsh,et al. Prospects for new antibiotics: a molecule-centered perspective , 2013, The Journal of Antibiotics.
[76] C. Serhan,et al. Identification and structure elucidation of the pro‐resolving mediators provides novel leads for resolution pharmacology , 2018, British journal of pharmacology.
[77] Mark E. B. Smith,et al. Acid-cleavable thiomaleamic acid linker for homogeneous antibody–drug conjugation† †Electronic supplementary information (ESI) available: 1H and 13C spectra for all novel compounds, and ES-MS spectra for all reactions with proteins described herein. See DOI: 10.1039/c3cc45220d Click here for additio , 2013, Chemical communications.
[78] P. Trail,et al. Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity. , 2002, Bioconjugate chemistry.
[79] Krister Wennerberg,et al. Rational Polypharmacology: Systematically Identifying and Engaging Multiple Drug Targets To Promote Axon Growth. , 2015, ACS chemical biology.
[80] Gerhard Klebe,et al. High-Throughput Crystallography: Reliable and Efficient Identification of Fragment Hits. , 2016, Structure.
[81] George Papadatos,et al. The ChEMBL bioactivity database: an update , 2013, Nucleic Acids Res..
[82] J. Pelletier,et al. Target identification using drug affinity responsive target stability (DARTS). , 2009, Proceedings of the National Academy of Sciences of the United States of America.
[83] Oleg A Raevsky,et al. Applications of Multi-Target Computer-Aided Methodologies in Molecular Design of CNS Drugs. , 2019, Current medicinal chemistry.
[84] M. Tancer,et al. The story of antipsychotics: Past and present , 2009, Indian journal of psychiatry.
[85] T. Wencewicz,et al. Biscatecholate-monohydroxamate mixed ligand siderophore-carbacephalosporin conjugates are selective sideromycin antibiotics that target Acinetobacter baumannii. , 2013, Journal of medicinal chemistry.
[86] R. Morphy,et al. Designed multiple ligands. An emerging drug discovery paradigm. , 2005, Journal of medicinal chemistry.
[87] M. McCarthy,et al. Cefiderocol: a novel siderophore cephalosporin , 2018, Expert opinion on investigational drugs.
[88] A. Čumová,et al. Natural compounds and combination therapy in colorectal cancer treatment. , 2018, European journal of medicinal chemistry.
[89] G. Rosano,et al. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome , 2005 .
[90] Richard S. Judson,et al. Profiling Bioactivity of the ToxCast Chemical Library Using BioMAP Primary Human Cell Systems , 2009, Journal of biomolecular screening.
[91] W. Ko,et al. Experimental animal models of Parkinson's disease: A transition from assessing symptomatology to α-synuclein targeted disease modification , 2017, Experimental Neurology.
[92] M. Pangalos,et al. Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework , 2014, Nature Reviews Drug Discovery.
[93] M. Scotti,et al. Hybrid Compounds as Direct Multitarget Ligands: A Review. , 2017, Current topics in medicinal chemistry.
[94] Jeffrey Aubé,et al. Drug repurposing and the medicinal chemist. , 2012, ACS medicinal chemistry letters.
[95] Ying Liu,et al. De Novo Design of Multitarget Ligands with an Iterative Fragment-Growing Strategy , 2014, J. Chem. Inf. Model..
[96] K. Shokat,et al. Targeting the cancer kinome through polypharmacology , 2010, Nature Reviews Cancer.
[97] Andreas Bender,et al. From in silico target prediction to multi-target drug design: current databases, methods and applications. , 2011, Journal of proteomics.
[98] Richard Morphy,et al. Fragments, network biology and designing multiple ligands. , 2007, Drug discovery today.
[99] E. Proschak,et al. A novel dual PPAR-γ agonist/sEH inhibitor treats diabetic complications in a rat model of type 2 diabetes , 2018, Diabetologia.
[100] S. Yamanaka,et al. Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors , 2006, Cell.
[101] Sandra K. Wittmann,et al. N-Benzylbenzamides: A Novel Merged Scaffold for Orally Available Dual Soluble Epoxide Hydrolase/Peroxisome Proliferator-Activated Receptor γ Modulators. , 2016, Journal of medicinal chemistry.
[102] Luhua Lai,et al. Dynamic Simulations on the Arachidonic Acid Metabolic Network , 2007, PLoS Comput. Biol..
[103] P. Senter,et al. Development and properties of beta-glucuronide linkers for monoclonal antibody-drug conjugates. , 2006, Bioconjugate chemistry.
[104] Kevan M. Shokat,et al. Chemical genetic discovery of targets and anti-targets for cancer polypharmacology , 2012, Nature.
[105] Hongyu Zhao,et al. Predicting synergistic effects between compounds through their structural similarity and effects on transcriptomes , 2016, Bioinform..
[106] S. Sakkiah,et al. An Innovative Strategy for Dual Inhibitor Design and Its Application in Dual Inhibition of Human Thymidylate Synthase and Dihydrofolate Reductase Enzymes , 2013, PloS one.
[107] R. Bowser,et al. Use of biomarkers in ALS drug development and clinical trials , 2015, Brain Research.
[108] Markus Hartenfeller,et al. De novo drug design. , 2010, Methods in molecular biology.
[109] Daniel Crespy,et al. Designing Smart Polymer Conjugates for Controlled Release of Payloads. , 2018, Chemical reviews.
[110] John P. Overington,et al. Can we rationally design promiscuous drugs? , 2006, Current opinion in structural biology.
[111] Cesare R Sirtori,et al. The pharmacology of statins. , 2014, Pharmacological research.
[112] Matthias Goebel,et al. Characterization of New PPARγ Agonists: Benzimidazole Derivatives – the Importance of Position 2 , 2009, ChemMedChem.
[113] Balaguru Ravikumar,et al. Improving the efficacy-safety balance of polypharmacology in multi-target drug discovery , 2018, Expert opinion on drug discovery.
[114] N. Nader,et al. Cardioprotection by Metformin: Beneficial Effects Beyond Glucose Reduction , 2018, American Journal of Cardiovascular Drugs.
[115] W. Boggess,et al. A Synthetic Dual Drug Sideromycin Induces Gram-Negative Bacteria To Commit Suicide with a Gram-Positive Antibiotic. , 2018, Journal of medicinal chemistry.
[116] G. Drewes,et al. Tracking cancer drugs in living cells by thermal profiling of the proteome , 2014, Science.
[117] Petra Schneider,et al. De Novo Design at the Edge of Chaos. , 2016, Journal of medicinal chemistry.
[118] A. Cavalli,et al. Navigating the Chemical Space of Multitarget-Directed Ligands: From Hybrids to Fragments in Alzheimer’s Disease , 2016, Molecules.
[119] Feng Xu,et al. Co-targeting cancer drug escape pathways confers clinical advantage for multi-target anticancer drugs. , 2015, Pharmacological research.
[120] O. Engkvist,et al. Merged Multiple Ligands , 2017 .
[121] Yuanjia Hu,et al. Network Analysis of Drug–target Interactions: A Study on FDA-approved New Molecular Entities Between 2000 to 2015 , 2017, Scientific Reports.
[122] Keith F. Tipton,et al. Multi-Target Directed Donepezil-Like Ligands for Alzheimer's Disease , 2016, Front. Neurosci..
[123] Jens-Uwe Peters,et al. Polypharmacology in Drug Discovery: Peters/Polypharmacology , 2012 .
[124] A. Petrelli,et al. Multitarget drugs: the present and the future of cancer therapy , 2009 .
[125] Anne W. Schmidt,et al. 3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents. , 1996, Journal of medicinal chemistry.
[126] Yi Sun,et al. Advances in computational approaches in identifying synergistic drug combinations , 2017, Briefings Bioinform..
[127] Andrew R. Leach,et al. Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery , 2001, J. Chem. Inf. Comput. Sci..
[128] Markus Hartenfeller,et al. DOGS: Reaction-Driven de novo Design of Bioactive Compounds , 2012, PLoS Comput. Biol..
[129] T. Yap,et al. Strategies for modern biomarker and drug development in oncology , 2014, Journal of Hematology & Oncology.
[130] Alan Talevi,et al. Multi-target pharmacology: possibilities and limitations of the “skeleton key approach” from a medicinal chemist perspective , 2015, Front. Pharmacol..
[131] M. Schubert-Zsilavecz,et al. The Linker Approach , 2017 .
[132] M. Schindler,et al. Designed multiple ligands in metabolic disease research: from concept to platform. , 2013, Drug discovery today.
[133] Jie Li,et al. Comparative Assessment of Scoring Functions on an Updated Benchmark: 1. Compilation of the Test Set , 2014, J. Chem. Inf. Model..
[134] M. Horowitz,et al. New insights into the anti-diabetic actions of metformin: from the liver to the gut , 2017, Expert review of gastroenterology & hepatology.
[135] Chris Sander,et al. Drug Synergy Screen and Network Modeling in Dedifferentiated Liposarcoma Identifies CDK4 and IGF1R as Synergistic Drug Targets , 2013, Science Signaling.
[136] V. Francardo,et al. Animal models of l-DOPA-induced dyskinesia: the 6-OHDA-lesioned rat and mouse , 2018, Journal of Neural Transmission.
[137] J. T. Jørgensen. The importance of predictive biomarkers in oncology drug development , 2016, Expert review of molecular diagnostics.
[138] Eytan Ruppin,et al. Harnessing synthetic lethality to predict the response to cancer treatment , 2018, Nature Communications.
[139] J. Aronson. In defence of polypharmacy. , 2004, British journal of clinical pharmacology.
[140] Antonio Lavecchia,et al. In silico methods to address polypharmacology: current status, applications and future perspectives. , 2016, Drug discovery today.
[141] M. Markman,et al. From serendipity to design: the evolution of drug development in oncology. , 1997, Cleveland Clinic journal of medicine.
[142] Luhua Lai,et al. Dynamic eicosanoid responses upon different inhibitor and combination treatments on the arachidonic acid metabolic network. , 2012, Molecular bioSystems.
[143] P. Nordlund,et al. Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay , 2013, Science.
[144] Petra Schneider,et al. Chemically Advanced Template Search (CATS) for Scaffold-Hopping and Prospective Target Prediction for ‘Orphan’ Molecules , 2013, Molecular informatics.
[145] W. Bolosky,et al. Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies , 2017, Proceedings of the National Academy of Sciences.
[146] S. Fox,et al. Serotonergic Approaches in Parkinson's Disease: Translational Perspectives, an Update. , 2017, ACS chemical neuroscience.
[147] B. Potter,et al. Aromatase and Dual Aromatase-Steroid Sulfatase Inhibitors from the Letrozole and Vorozole Templates , 2011, ChemMedChem.
[148] Adam J. Lewis,et al. High-throughput identification and rational design of synergistic small-molecule pairs for combating and bypassing antibiotic resistance , 2017, PLoS biology.
[149] D. Steinhilber,et al. Small molecules with anti-inflammatory properties in clinical development. , 2016, Pharmacology & therapeutics.
[150] L. Silver,et al. Multitarget ligands in antibacterial research: progress and opportunities , 2013, Expert opinion on drug discovery.
[151] Weilin Zhang,et al. Computational Multitarget Drug Design , 2017, J. Chem. Inf. Model..
[152] A. Mantel‐Teeuwisse,et al. Drug repositioning and repurposing: terminology and definitions in literature. , 2015, Drug discovery today.
[153] Gerd Geisslinger,et al. A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase To Counter Nonalcoholic Steatohepatitis. , 2017, Journal of medicinal chemistry.
[154] M. Papp,et al. S32212, a Novel Serotonin Type 2C Receptor Inverse Agonist/α2-Adrenoceptor Antagonist and Potential Antidepressant: II. A Behavioral, Neurochemical, and Electrophysiological Characterization , 2012, Journal of Pharmacology and Experimental Therapeutics.
[155] N. Cohen,et al. The NEWLEAD program: a new method for the design of candidate structures from pharmacophoric hypotheses. , 1993, Journal of medicinal chemistry.
[156] Rolf Larsson,et al. Bliss and Loewe interaction analyses of clinically relevant drug combinations in human colon cancer cell lines reveal complex patterns of synergy and antagonism , 2017, Oncotarget.
[157] Thierry Langer,et al. LigandScout: 3-D Pharmacophores Derived from Protein-Bound Ligands and Their Use as Virtual Screening Filters , 2005, J. Chem. Inf. Model..
[158] Ondřej Soukup,et al. Multitarget-Directed Ligands Combining Cholinesterase and Monoamine Oxidase Inhibition with Histamine H3 R Antagonism for Neurodegenerative Diseases. , 2017, Angewandte Chemie.
[159] Dmitri B. Kireev,et al. Structural Protein–Ligand Interaction Fingerprints (SPLIF) for Structure-Based Virtual Screening: Method and Benchmark Study , 2014, J. Chem. Inf. Model..
[160] N. Dempster,et al. Phenothiazinium-fluoroquinolone drug conjugates. , 2010, International journal of antimicrobial agents.
[161] P. Ernsberger,et al. The SHROB Model of Syndrome X: Effects of Excess Dietary Sucrose , 1999, Annals of the New York Academy of Sciences.
[162] Richard Morphy,et al. Designing multiple ligands - medicinal chemistry strategies and challenges. , 2009, Current pharmaceutical design.
[163] S. Leucht,et al. Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis , 2018, European Archives of Psychiatry and Clinical Neuroscience.
[164] L. Polito,et al. 3,4-Dihydro-1,3,5-triazin-2(1H)-ones as the First Dual BACE-1/GSK-3β Fragment Hits against Alzheimer's Disease. , 2015, ACS chemical neuroscience.
[165] J. Lehár,et al. Multi-target therapeutics: when the whole is greater than the sum of the parts. , 2007, Drug discovery today.
[166] Peng Zhan,et al. Designed multiple ligands: an emerging anti-HIV drug discovery paradigm. , 2009, Current pharmaceutical design.
[167] W. Geldenhuys,et al. Rationally designed multi-targeted agents against neurodegenerative diseases. , 2013, Current medicinal chemistry.
[168] Anthony Watts,et al. Dynamic tuneable G protein-coupled receptor monomer-dimer populations , 2018, Nature Communications.
[169] Michael Decker,et al. The dual-acting H3 receptor antagonist and AChE inhibitor UW-MD-71 dose-dependently enhances memory retrieval and reverses dizocilpine-induced memory impairment in rats , 2016, Behavioural Brain Research SreeTestContent1.
[170] David Rogers,et al. Extended-Connectivity Fingerprints , 2010, J. Chem. Inf. Model..
[171] C. Wermuth. Selective optimization of side activities: another way for drug discovery. , 2004, Journal of medicinal chemistry.
[172] J. Schwartz,et al. Search for Histamine H3 Receptor Ligands with Combined Inhibitory Potency at Histamine N‐Methyltransferase: ω‐Piperidinoalkanamine Derivatives , 2004, Archiv der Pharmazie.
[173] Andreas Bender,et al. Analyzing Multitarget Activity Landscapes Using Protein-Ligand Interaction Fingerprints: Interaction Cliffs , 2015, J. Chem. Inf. Model..
[174] B. Rolando,et al. Designing Multitarget Anti‐inflammatory Agents: Chemical Modulation of the Lumiracoxib Structure toward Dual Thromboxane Antagonists–COX‐2 Inhibitors , 2012, ChemMedChem.
[175] A. Hopkins. Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.
[176] John P. Overington,et al. The promise and peril of chemical probes. , 2015, Nature chemical biology.
[177] R. Albin,et al. Serotonin, β‐amyloid, and cognition in Parkinson disease , 2018, Annals of neurology.
[178] Sahdeo Prasad,et al. Serendipity in Cancer Drug Discovery: Rational or Coincidence? , 2016, Trends in pharmacological sciences.
[179] Weiwei Xue,et al. The Human Kinome Targeted by FDA Approved Multi-Target Drugs and Combination Products: A Comparative Study from the Drug-Target Interaction Network Perspective , 2016, PloS one.
[180] Z. Kovács,et al. Charting the chemical space around the (iso)indoline scaffold, a comprehensive approach towards multitarget directed ligands. , 2016, Bioorganic & medicinal chemistry letters.
[181] J. Chen,et al. Design, synthesis, and evaluation of imidazo[4,5-c]pyridin-4-one derivatives with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ. , 2013, Bioorganic & medicinal chemistry letters.
[182] D. Steinhilber,et al. Boosting Anti-Inflammatory Potency of Zafirlukast by Designed Polypharmacology. , 2018, Journal of medicinal chemistry.
[183] V. Braun,et al. Sideromycins: tools and antibiotics , 2009, BioMetals.
[184] T. Long,et al. Trihydroxamate siderophore-fluoroquinolone conjugates are selective sideromycin antibiotics that target Staphylococcus aureus. , 2013, Bioconjugate chemistry.
[185] Hongchun Li,et al. Connecting Neuronal Cell Protective Pathways and Drug Combinations in a Huntington’s Disease Model through the Application of Quantitative Systems Pharmacology , 2017, Scientific Reports.
[186] Harren Jhoti,et al. High-throughput crystallography for lead discovery in drug design , 2002, Nature Reviews Drug Discovery.
[187] L Costantino,et al. Designed multiple ligands: basic research vs clinical outcomes. , 2012, Current medicinal chemistry.
[188] D. Grillot,et al. Discovery of novel indazole derivatives as dual angiotensin II antagonists and partial PPARγ agonists. , 2014, Bioorganic & medicinal chemistry letters.
[189] Jordi Mestres,et al. Polypharmacology in Precision Oncology: Current Applications and Future Prospects , 2016, Current pharmaceutical design.
[190] Hugues-Olivier Bertrand,et al. Are You Sure You Have a Good Model , 2006 .
[191] L. Silver,et al. Multi-targeting by monotherapeutic antibacterials , 2007, Nature Reviews Drug Discovery.
[192] Jörn Lötsch,et al. Low-dose drug combinations along molecular pathways could maximize therapeutic effectiveness while minimizing collateral adverse effects. , 2011, Drug discovery today.
[193] J. Doudna,et al. The new frontier of genome engineering with CRISPR-Cas9 , 2014, Science.
[194] Xing Chen,et al. NLLSS: Predicting Synergistic Drug Combinations Based on Semi-supervised Learning , 2016, PLoS Comput. Biol..
[195] B. Admire,et al. Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology. , 2015, Angewandte Chemie.
[196] T. Grosser,et al. A broad-spectrum lipidomics screen of antiinflammatory drug combinations in human blood. , 2016, JCI insight.
[197] B. Potter,et al. Dual aromatase-steroid sulfatase inhibitors. , 2007, Journal of medicinal chemistry.
[198] S. Abramson,et al. The pleiotropic functions of aspirin: mechanisms of action , 1999, Cellular and Molecular Life Sciences CMLS.
[199] S. Fulda,et al. Structure-activity studies on N-Substituted tranylcypromine derivatives lead to selective inhibitors of lysine specific demethylase 1 (LSD1) and potent inducers of leukemic cell differentiation. , 2018, European journal of medicinal chemistry.
[200] Y. Martin,et al. Do structurally similar molecules have similar biological activity? , 2002, Journal of medicinal chemistry.
[201] Daniel Moser,et al. Exploring the chemical space of multitarget ligands using aligned self-organizing maps. , 2013, ACS medicinal chemistry letters.
[202] Arthur Christopoulos,et al. Orthosteric/allosteric bitopic ligands: going hybrid at GPCRs. , 2009, Molecular interventions.
[203] C. Sigman,et al. Cancer biomarkers: selecting the right drug for the right patient , 2012, Nature Reviews Drug Discovery.
[204] Ewgenij Proschak,et al. Opportunities and Challenges for Fatty Acid Mimetics in Drug Discovery. , 2017, Journal of medicinal chemistry.
[205] M. Battino,et al. The use of natural compounds for the targeting and chemoprevention of ovarian cancer. , 2017, Cancer letters.
[206] D. Merk,et al. Therapeutic Potential of Peroxisome Proliferator-Activated Receptor Modulation in Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis , 2017 .
[207] V. Pillay,et al. Multi-target therapeutics for neuropsychiatric and neurodegenerative disorders. , 2016, Drug discovery today.
[208] M. Millan,et al. S32212, a Novel Serotonin Type 2C Receptor Inverse Agonist/α2-Adrenoceptor Antagonist and Potential Antidepressant: I. A Mechanistic Characterization , 2012, Journal of Pharmacology and Experimental Therapeutics.
[209] G. Drewes,et al. Thermal proteome profiling monitors ligand interactions with cellular membrane proteins , 2015, Nature Methods.
[210] Thierry Langer,et al. Selective Optimization of Side Activities (SOSA): A Promising way for Drug Discovery , 2012 .
[211] Hongma Sun,et al. Pharmacophore-based virtual screening. , 2008, Current medicinal chemistry.
[212] U. McDermott,et al. High-throughput RNAi screen for essential genes and drug synergistic combinations in colorectal cancer , 2017, Scientific Data.
[213] M. Suckow,et al. Targeted Antibiotic Delivery: Selective Siderophore Conjugation with Daptomycin Confers Potent Activity against Multidrug Resistant Acinetobacter baumannii Both in Vitro and in Vivo. , 2017, Journal of medicinal chemistry.
[214] Li Wang,et al. Donepezil + propargylamine + 8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer's disease. , 2014, European journal of medicinal chemistry.
[215] Sean Ekins,et al. In silico repositioning of approved drugs for rare and neglected diseases. , 2011, Drug discovery today.
[217] Sourav Bandyopadhyay,et al. A Quantitative Chemotherapy Genetic Interaction Map Reveals Factors Associated with PARP Inhibitor Resistance , 2018, Cell reports.
[218] Luhua Lai,et al. Discovery of multitarget inhibitors by combining molecular docking with common pharmacophore matching. , 2008, Journal of medicinal chemistry.
[219] Cristina Tintori,et al. Targets Looking for Drugs: A Multistep Computational Protocol for the Development of Structure-Based Pharmacophores and Their Applications for Hit Discovery , 2008, J. Chem. Inf. Model..
[220] R. Glennon,et al. 5-HT1 and 5-HT2 binding characteristics of some quipazine analogues. , 1986, Journal of medicinal chemistry.
[221] Bernhard Kuster,et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors , 2007, Nature Biotechnology.
[222] Maria F. Sassano,et al. Automated design of ligands to polypharmacological profiles , 2012, Nature.
[223] Richard Morphy,et al. The physicochemical challenges of designing multiple ligands. , 2006, Journal of medicinal chemistry.
[224] Rona R. Ramsay,et al. A perspective on multi-target drug discovery and design for complex diseases , 2018, Clinical and Translational Medicine.
[225] G. Lip,et al. Effects of Aspirin on Endothelial Function and Hypertension , 2016, Current Hypertension Reports.
[226] S. Laufer,et al. Discovery of N-{4-[5-(4-Fluorophenyl)-3-methyl-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-acetamide (CBS-3595), a Dual p38α MAPK/PDE-4 Inhibitor with Activity against TNFα-Related Diseases. , 2017, Journal of medicinal chemistry.
[227] D. Sall,et al. Modern phenotypic drug discovery is a viable, neoclassic pharma strategy. , 2012, Journal of medicinal chemistry.
[228] Maurizio Recanatini,et al. The role of fragment-based and computational methods in polypharmacology. , 2012, Drug discovery today.
[229] J. Medina-Franco,et al. Shifting from the single to the multitarget paradigm in drug discovery. , 2013, Drug discovery today.
[230] Herbert Waldmann,et al. Target identification for small bioactive molecules: finding the needle in the haystack. , 2013, Angewandte Chemie.
[231] Dominik Dolles,et al. Structure-Activity Relationships and Computational Investigations into the Development of Potent and Balanced Dual-Acting Butyrylcholinesterase Inhibitors and Human Cannabinoid Receptor 2 Ligands with Pro-Cognitive in Vivo Profiles. , 2018, Journal of medicinal chemistry.